Nisa Investment Advisors’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $99.5K | Buy |
1,326
+677
| +104% | +$43.5K | ﹤0.01% | 1551 |
|
|
2026
Q1 | $36.6K | Buy |
649
+26
| +4% | +$1.69K | ﹤0.01% | 1799 |
|
|
2025
Q4 | $49.9K | Buy |
623
+62
| +11% | +$4.17K | ﹤0.01% | 1616 |
|
|
2025
Q3 | $27.3K | Sell |
561
-909
| -62% | -$56.3K | ﹤0.01% | 1854 |
|
|
2025
Q2 | $110K | Buy |
1,470
+677
| +85% | +$44.8K | ﹤0.01% | 1364 |
|
|
2025
Q1 | $50.4K | Sell |
793
-402
| -34% | -$27.3K | ﹤0.01% | 1591 |
|
|
2024
Q4 | $93.3K | Buy |
1,195
+54
| +5% | +$4.34K | ﹤0.01% | 1494 |
|
|
2024
Q3 | $91.7K | Buy |
1,141
+632
| +124% | +$51.1K | ﹤0.01% | 1471 |
|
|
2024
Q2 | $42.1K | Buy |
509
+44
| +9% | +$3.87K | ﹤0.01% | 1714 |
|
|
2024
Q1 | $39.7K | Buy |
465
+38
| +9% | +$2.98K | ﹤0.01% | 1712 |
|
|
2023
Q4 | $36.5K | Sell |
427
-800
| -65% | -$69.2K | ﹤0.01% | 1707 |
|
|
2023
Q3 | $110K | Sell |
1,227
-100
| -8% | -$8.93K | ﹤0.01% | 1477 |
|
|
2023
Q2 | $113K | Hold |
1,327
| – | – | ﹤0.01% | 1476 |
|
|
2023
Q1 | $110K | Buy |
1,327
+1
| +0.1% | +$81 | ﹤0.01% | 1478 |
|
|
2022
Q4 | $104K | Hold |
1,326
| – | – | ﹤0.01% | 1543 |
|
|
2022
Q3 | $112K | Buy |
1,326
+71
| +6% | +$5.1K | ﹤0.01% | 1451 |
|
|
2022
Q2 | $82K | Hold |
1,255
| – | – | ﹤0.01% | 1558 |
|
|
2022
Q1 | $79K | Sell |
1,255
-170
| -12% | -$9.24K | ﹤0.01% | 1702 |
|
|
2021
Q4 | $69K | Hold |
1,425
| – | – | ﹤0.01% | 1637 |
|
|
2021
Q3 | $101K | Hold |
1,425
| – | – | ﹤0.01% | 1696 |
|
|
2021
Q2 | $95K | Buy |
1,425
+1,360
| +2,092% | +$96.2K | ﹤0.01% | 1719 |
|
|
2021
Q1 | $7K | Hold |
65
| – | – | ﹤0.01% | 2241 |
|
|
2020
Q4 | $8K | Hold |
65
| – | – | ﹤0.01% | 2240 |
|
|
2020
Q3 | $6K | Hold |
65
| – | – | ﹤0.01% | 2180 |
|
|
2020
Q2 | $6K | Sell |
65
-305
| -82% | -$30.8K | ﹤0.01% | 1996 |
|
|
2020
Q1 | $37K | Sell |
370
-20
| -5% | -$2.17K | ﹤0.01% | 1591 |
|
|
2019
Q4 | $45K | Sell |
390
-1,190
| -75% | -$144K | ﹤0.01% | 1544 |
|
|
2019
Q3 | $199K | Buy |
1,580
+1,330
| +532% | +$169K | ﹤0.01% | 1326 |
|
|
2019
Q2 | $30K | Hold |
250
| – | – | ﹤0.01% | 1562 |
|
|
2019
Q1 | $22K | Hold |
250
| – | – | ﹤0.01% | 1607 |
|
|
2018
Q4 | $25K | Sell |
250
-18,505
| -99% | -$1.94M | ﹤0.01% | 1507 |
|
|
2018
Q3 | $2.15M | Buy |
18,755
+18,485
| +6,846% | +$1.91M | 0.02% | 633 |
|
|
2018
Q2 | $24K | Hold |
270
| – | – | ﹤0.01% | 1520 |
|
|
2018
Q1 | $20K | Sell |
270
-50
| -16% | -$3.43K | ﹤0.01% | 1485 |
|
|
2017
Q4 | $19K | Hold |
320
| – | – | ﹤0.01% | 1560 |
|
|
2017
Q3 | $14K | Hold |
320
| – | – | ﹤0.01% | 1635 |
|
|
2017
Q2 | $13K | Hold |
320
| – | – | ﹤0.01% | 1626 |
|
|
2017
Q1 | $13K | Sell |
320
-280
| -47% | -$10.9K | ﹤0.01% | 1592 |
|
|
2016
Q4 | $24K | Hold |
600
| – | – | ﹤0.01% | 1575 |
|
|
2016
Q3 | $22K | Hold |
600
| – | – | ﹤0.01% | 1621 |
|
|
2016
Q2 | $17K | Hold |
600
| – | – | ﹤0.01% | 1672 |
|
|
2016
Q1 | $21K | Buy |
+600
| New | +$19.4K | ﹤0.01% | 1589 |
|
Other funds holding HAE
AI
Nisa Investment Advisors's HAE Position: Q2 2026 in Review
Nisa Investment Advisors increased its Haemonetics (HAE) stake by 104% in Q2 2026, buying an estimated $43.5K and bringing the position to 1,326 shares worth $99.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1551.
Nisa Investment Advisors first reported a position in HAE in Q1 2016 and has held it in 42 quarters since. The position peaked at $2.15M in Q3 2018. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.
- Nisa Investment Advisors held 1,326 shares of Haemonetics worth $99.5K as of Q2 2026.
- Nisa Investment Advisors bought 677 Haemonetics shares in Q2 2026, an estimated $43.5K.
- Haemonetics made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #1551 holding.
- Nisa Investment Advisors first reported a position in Haemonetics in Q1 2016 and has held it in 42 quarters since.
- Nisa Investment Advisors's Haemonetics position peaked at $2.15M in Q3 2018.
- 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.
Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.